Sovenyr Get early access

Signal2026-07-24

EPO Patents

[EPO] CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-2

Part of

Early Phase Immune Therapeutics Trials

Open primary source See the whole picture

Powered by Sovenyr — cross-source signal intelligence. Figures are collected data as-dated, not investment advice.